Theravance Inc. (THRX) and GlaxoSmithKline (GSK) announced the initial outcomes from Phase III studies of once-daily Relovair Monday morning.
Theravance gapped open sharply lower Monday and has continued to fall on above average volume in early trade. The stock is now down 7.19 at $13.01 and has dropped to a new low for the year.
For comments and feedback: editorial@rttnews.com